MedX Health Corp. Announces Inaugural Clinical Trial of Leading-Edge Teledermatology Screening Platform in Turkey
17 November 2021 - 10:15PM
Business Wire
Clinical Trial of MedX’s DermSecure® Platform
to include three university hospitals
MedX Health Corp. (“MedX” or the “Company”) (TSXV:
MDX) is pleased to announce an inaugural clinical trial of its
leading-edge DermSecure® Screening Platform at three university
hospitals across Turkey in early 2022.
Through its recently announced distribution agreement with
Makromed/Arhan Global A.Ş, MedX’s DermSecure® Screening Platform
will be used in a clinical trial overseen by noted Turkish
dermatologist, Dr. Emel Erdal Çalikoğlu a Professor of Dermatology
at Dokuz Eylül University in İzmir, Turkey. The clinical trial will
also include Kocaeli University, led by Professor of Dermatology,
Dr. Dilek Bayramgürler, as well as Bursa Uludağ University, led by
Professor of Dermatology, Dr. Emel Bülbül Başkan and Associate
Professor, Dr. Serkan Yazici.
The clinical trial will run for 6 months and involve an
estimated 300 patients throughout Turkey. Following its successful
completion, MedX and its distribution partner Makromed/Arhan Global
A.Ş, anticipate the technology will become more widely available in
clinics, pharmacies and insurance companies across the country.
This study builds on MedX’s existing European commercialization
pilots in the Netherlands and Italy, as part of the company’s
global commercialization strategy. Additional commercialization
pilots are anticipated in the coming months.
“There are types of melanoma tumors which we can more
effectively treat by early detection. As such, I strongly believe
that MedX’s SIAscopy® and DermSecure® can help our fight against
melanoma,” said Dr. Emel Erdal Çalikoğlu. “We look forward
to seeing the results of this study and bringing MedX’s world-class
teledermatology device and platform to those dermatology patients
who need it most. Using MedX’s innovative technology should become
part of dermatologists’ daily practice.”
Sylvain Desjeans, MedX CEO, said, “This inaugural clinical trial
marks an important first step in establishing our technology and
path to reimbursement in medical facilities across Turkey, a market
of more than 80 million people. It’s a significant milestone in our
global commercialization strategy.”
“Working with such notable dermatologists as Dr. Çalikoğlu means
securing a strong, credible foothold with the dermatology community
in the Turkish market,” added Chantal Ward, MedX Director, Medical
Affairs. “We eagerly anticipate the results of the study, and the
positive impact it will have on skin health patients across the
country.”
Naman Demaghlatrous, MedX Managing Director of Europe, Middle
East and Africa, said, “With the clinical trial and distribution
agreement with Makromed, this market shows incredible growth
potential for MedX – both in terms of increasing patient access and
establishing reimbursement through the Turkish healthcare system.
We look forward to leveraging this growth opportunity as one of
many in Europe and beyond.”
Teledermatology is a subspecialty of dermatology that offers
safe and effective virtual care – patient screening and assessment
– eliminating the need for in-person appointments with a
dermatologist. Unlike other teledermatology screening tools
available, MedX’s DermSecure® Screening Platform features
high-resolution image capture technology for moles, lesions and
other skin conditions; providing a complete, virtual dermatological
assessment by a certified dermatologist within just 72 hours.
MedX’s leading telemedicine platform allows health-care
practitioners to quickly and accurately assess suspicious moles,
lesions and other skin conditions via its image capture technology,
SIAscopy®, and its secure, cloud-based patient management system,
DermSecure®, which transmits and stores patient data throughout the
assessment process. MedX’s SIAscopy® is the only technology that
captures five images, including four spectrophotometric images 2mm
below the skin’s surface.
About MedX:
MedX, headquartered in Ontario, Canada, is a leading medical
device and software company focused on skin health with its
SIAscopy® on DermSecure® telemedicine platform, utilizing its
SIAscopy® technology. SIAscopy® is also imbedded in its products
SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its
ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate®
include hand-held devices that use patented technology utilizing
light and its remittance to view up to 2 mm beneath suspicious
moles and lesions in a pain free, non-invasive manner, with its
software then creating real-time images for physicians and
dermatologists to evaluate all types of moles or lesions within
seconds. These products are cleared by Health Canada, the U.S. Food
and Drug Administration, the Therapeutic Goods Administration and
Conformité Européenne for use in Canada, the US, Australia, New
Zealand, the European Union, Brazil and Turkey. Visit https://medxhealth.com.
Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
This Media Release may contain forward-looking statements, which
reflect the Company’s current expectations regarding future events.
The forward-looking statements involve risks and uncertainties.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211117006318/en/
Bill Mitoulas, Investor Relations MedX Health
Corp. bill@medxhealth.com +1-416-479-9547
Medx Health (TSXV:MDX)
Historical Stock Chart
Von Dez 2024 bis Jan 2025
Medx Health (TSXV:MDX)
Historical Stock Chart
Von Jan 2024 bis Jan 2025